Character Biosciences Secures $93 Million to Revolutionize AMD Treatment with Novel Drug Candidates March 25, 2025
Revolutionary Gene Editing Therapy VERVE-102 Receives FDA Approval to Transform Cholesterol Treatment Landscape March 25, 2025
Revolutionizing Cholesterol Management: Verve Therapeutics Gains FDA Nod for Groundbreaking Gene Editing Trial March 25, 2025
Revolutionary Gene Editing Treatment VERVE-102 Expands to U.S. Trials, Promising Permanent Cholesterol Reduction March 24, 2025
Novo Nordisk Bolsters Obesity Drug Pipeline with $200 Million Acquisition of Promising Triple Agonist UBT251 March 24, 2025
Revolutionizing Pharmacy Payments: Optum Rx’s Bold Shift to Cost-Based Reimbursement and Its Impact on Access to Medications March 24, 2025
Optum Rx Unveils Cost-Based Payment Model: A Game Changer for Pharmacy Reimbursement Practices March 24, 2025
Revolutionizing Pharmacy Payments: Optum Rx’s New Cost-Based Reimbursement Model Aims to Transform Drug Dispensing Landscape March 23, 2025
Optum Rx Transitions to Cost-Based Payment Model: A Potential Game Changer for Pharmacies March 23, 2025
